Effects of Jie Yu Wan on Generalized Anxiety Disorder: A Randomized Clinical Trial

Table 1

Demographic and baseline data (x ± s).

	JYW (n = 66), n (%)	Buspirone (n = 67), n (%)	t/x^2
Age	46.96 ± 12.31	45.55 ± 10.84	0.70	0.49
<30	8 (12.12%)	5 (7.5%)
30–50	28 (42.42%)	35 (52.23%)
>50	29 (43.94%)	27 (40.29%)
Gender
Male	22 (33.33%)	21 (31.34%)	1.03	0.60
Female	44 (66.67%)	46 (68.57%)
Race
Han	65 (98.48%)	64 (95.52%)	−0.58	0.56
Minorities	1 (1.5%)	2 (3%)
Educational level
Primary education or less	6 (9.1%)	8 (12.94%)	0.33	0.74
Secondary education	32 (48.48%)	34 (50.75%)
Tertiary education	28 (42.42%)	25 (37.31%)
Duration	0.5 (0,1.85)	0.67 (0,2.08)	−0.71	0.48
≤12 months	36 (54.55%)	36 (53.73%)
12 < months < 25	16 (24.24%)	15 (22.39%)
25 < months < 36	6 (9.1%)	5 (7.5%)
>36 months	8 (12.12%)	11 (16.42%)
Baseline HAMA^a	18.95 (4.07)	19.09 ± 3.92	−0.57	0.57
14 ≤ HAMA ≤ 21	51 (77.27)	47 (70.15)
21 ＜ HAMA ≤ 29	15 (22.73)	20 (29.85)
Baseline HAMD^a	6.79 ± 1.26	6.87 ± 1.39	−0.41	0.68
Baseline CGI^a	3.73 ± 0.97	3.80 ± 0.83	−0.77	0.67
Baseline TCM syndrome^a	102.42 ± 38.12	99.52 ± 42.39	0.50	0.62

^aData are presented as n (%) or mean (SD). Duration: the disease duration of GAD.